Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts. Show more

Location: 490 Arsenal Way, Watertown, MA, 02472, United States | Website: https://tectonictx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

422.7M

52 Wk Range

$13.70 - $61.07

Previous Close

$21.72

Open

$21.27

Volume

382,402

Day Range

$20.78 - $22.96

Enterprise Value

67.41M

Cash

306.2M

Avg Qtr Burn

-15.72M

Insider Ownership

38.29%

Institutional Own.

59.27%

Qtr Updated

03/31/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TX45 Details Pulmonary hypertension in Heart failure with preserved Ejection Fraction (PH-HFpEF)	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TX45 Details Pulmonary Hypertension in Heart Failure with reduced Ejection Fraction (PH-HFrEF)	Phase 1b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.